Terpenes-Enriched CBD-Predominant Oil not checked
FollowEvery change as it happens, and a Monday email
Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Oral cannabidiol (CBD; 7.2 mg/kg/day), tetrahydrocannabinol (THC; 0.257 mg/kg/day, equivalent to 1:28 of the CBD dose), and terpenes (0.5 mg/kg/day), administered in two daily doses. The formulation is an olive oil-based solution (CBD/THC: 280/10 mg per g) produced by Bazelet Group, Israel.”In the company’s words, NCT07199218 on ClinicalTrials.gov
- Tested for
- Autism, Autism Spectrum Disorder
- Main trialPhase 2
- “The goal of this clinical trial is to determine whether cannabidiol (CBD, 28%) combined with terpenes and a small amount of THC (1%) can help reduce symptoms of autism, and to evaluate the safety of this treatment. The main questions are: 1. Does this treatment improve behavioral challenges in children with autism? 2. Does this treatment improve social difficulties in children with autism? What will happen in the study: 1. Participants take either the study treatment or a placebo (a look-alike substance with no active drug) every day for 2 months. 2. After 2 months, all participants…”In the company’s words, NCT07199218 on ClinicalTrials.gov
Other drugs for Autism
- CM-ATCuremark · Phase 3
- NTI164Fenix Innovation Group · Phase 3
- CodabakalnerSpinogenix · Phase 2/3
- Xanomeline/Trospium ChlorideBristol Myers Squibb · Phase 3
- ML-004MapLight Therapeutics · Phase 2
- Use autologous cSVFBlack Tie Medical, Inc. · Phase 1/2
Coming up1
- 31 Dec 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 31 Dec 2027 | Placebo-Controlled Study of Terpenes-Enriched Cannabis Oil T1/C28 for Children With Autism |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026